(86 days)
No
The device description and performance studies focus on the mechanical properties and deployment of a stent, with no mention of AI/ML or related concepts like image processing, training/test sets, or performance metrics typically associated with AI/ML algorithms.
Yes
The device is a prosthesis designed to treat a medical condition (biliary strictures) by maintaining the inner lumen diameter of the biliary duct, which aligns with the definition of a therapeutic device.
No
The device is a self-expanding prosthesis (stent) used to treat biliary strictures, which is a therapeutic function rather than a diagnostic one.
No
The device description clearly states it is a physical, self-expanding prosthesis constructed of biomedical superalloy and an elastomeric polymer, and includes a delivery system. This is a hardware device, not software only.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is the "treatment of biliary strictures produced by malignant neoplasms." This describes a therapeutic intervention, not a diagnostic test performed on samples taken from the body.
- Device Description: The device is a "self-expanding prosthesis" designed to "increase or maintain the inner lumen diameter of the biliary duct." This is a physical implant used to treat a condition within the body.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples (blood, urine, tissue, etc.), detecting specific analytes, or providing diagnostic information based on laboratory testing.
IVD devices are used to examine specimens derived from the human body to provide information for diagnostic, monitoring, or compatibility purposes. This device is a therapeutic implant.
N/A
Intended Use / Indications for Use
The WALLSTENT® Biliary Endoprosthesis is intended for use in the treatment of biliary strictures produced by malignant neoplasms.
The Schneider WALLSTENT® Biliary Endoprosthesis is indicated for use in the treatment of biliary strictures produced by malignant neoplasms.
Product codes (comma separated list FDA assigned to the subject device)
78 FGE
Device Description
The WALLSTENT® Biliary Endoprosthesis is a self-expanding prosthesis constructed of biomedical superalloy and an elastomeric polymer. The prosthesis is a braided wire structure. The outward radial force along with the ends of the device serve to stabilize the prosthesis after implanted. The stent's purpose is to increase or maintain the inner lumen diameter of the biliary duct.
The stent is placed by means of a delivery system. The delivery system is a coaxial tubing assembly that constrains the prosthesis until it is released in a controlled manner. The release of the stent is accomplished by retracting the outer sheath. The prosthesis is packaged constrained on the delivery system ready for placement. The system is sterile and intended for single use only.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
biliary tract/duct
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The alternate delivery system can be found substantially equivalent based on the results of in vitro and in vivo deployment testing which demonstrate that deployment forces and handling characteristics are comparable to the current delivery systems.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 876.5010 Biliary catheter and accessories.
(a)
Identification. A biliary catheter and accessories is a tubular flexible device used for temporary or prolonged drainage of the biliary tract, for splinting of the bile duct during healing, or for preventing stricture of the bile duct. This generic type of device may include a bile collecting bag that is attached to the biliary catheter by a connector and fastened to the patient with a strap.(b)
Classification. Class II (special controls). The device, when it is a bile collecting bag or a surgical biliary catheter that does not include a balloon component, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.
0
2 1998 SEP
16. 510(k) Summary |
---|
-------------------- |
Date Prepared | June 4, 1998 |
---|---|
Submitter | |
Address: | Schneider (USA) Inc |
5905 Nathan Lane | |
Minneapolis, MN 55442 | |
Phone : | (612) 550-5500 |
Fax : | (612) 550-5771 |
Contact Person | Ronald W. Bennett |
Senior Regulatory Affairs Specialist |
Device Name and Classification | |
---|---|
-------------------------------- | -- |
| Trade Name | WALLSTENT® Biliary Transhepatic
Endoprosthesis with Unistep™ Plus Delivery
System |
|-------------------|---------------------------------------------------------------------------------------------------------------------|
| Common Name | Biliary Stent |
| Classification | Class II |
| Predicate Devices | WALLSTENT® Biliary Transhepatic
Endoprosthesis with Unistep™ Plus Delivery
System - K923993, K961262, K964119 |
Device Description
The WALLSTENT® Biliary Endoprosthesis is a self-expanding prosthesis constructed of biomedical superalloy and an elastomeric polymer. The prosthesis is a braided wire structure. The outward radial force along with the ends of the device serve to stabilize the prosthesis after implanted. The stent's purpose is to increase or maintain the inner lumen diameter of the biliary duct.
The stent is placed by means of a delivery system. The delivery system is a coaxial tubing assembly that constrains the prosthesis until it is released in a controlled manner. The release of the stent is accomplished by retracting the outer sheath. The prosthesis is packaged constrained on the delivery system ready for placement. The system is sterile and intended for single use only.
1
Indication
The WALLSTENT® Biliary Endoprosthesis is intended for use in the treatment of biliary strictures produced by malignant neoplasms.
1982005
Technological Characteristics
The purpose of this 510(k) is to allow an alternate delivery system. Compared to the Unistep™ Delivery System (K961262, K923993), the Unistep™ Plus delivery system allows the user to partially deploy and then reconstrain the stent to facilitate placement. Compared to the present Unistep™ Plus Delivery System (K964119), the modified system has different materials for the outer and inner tubing. This feature is presently available for the 12 mm stent with the change in materials in the WALLSTENT® Tracheobronchial Endoprosthesis with Unistep™ Plus Delivery System (K980163).
The alternate delivery system can be found substantially equivalent based on the results of in vitro and in vivo deployment testing which demonstrate that deployment forces and handling characteristics are comparable to the current delivery systems.
Summary
In summary Schneider (USA) Inc has demonstrated that the WALLSTENT® Biliary Endoprosthesis with Unister ™ Plus Delivery System with modified delivery system is substantially equivalent based on design, test results, and indications for use to the predicate devices.
2
Image /page/2/Picture/0 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three stripes representing the department's mission. The text "DEPARTMENT OF HEALTH & HUM." is arranged in a semi-circle around the left side of the eagle, and the text "SERVICES - USA" is arranged in a semi-circle around the right side of the eagle.
DEPARTMENT OF HEALTH & HUMAN SERVICES
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
2 1998 SEP
Mr. Ronald W. Bennett Senior Regulatory Affairs Specialist Schneider (USA) Inc. Pfizer Medical Technology Group 5905 Nathan Lane Minneapolis, MN 55442
Re: K982005
WALLSTENT® with Unistep™ Plus (Biliary Stent and Catheter) Dated: June 4, 1998 Received: June 8, 1998 Regulatory Class: II 21 CFR 876.5010/Procode: 78 FGE
Dear Mr. Bennett:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (OS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4613. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address "http://www.fda.gov/odrh/dsmaldsmamain.html".
Sincerely yours
Lillian Yin, Ph.D.
Director, Division of Reproducti Abdominal, Ear, Nose and Throat and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
3
Page _________________________________________________________________________________________________________________________________________________________________________
510(k) Number (if known):
Schneider WALLSTENT® Biliary Endoprosthesis Device Name:
Indications for Use:
The Schneider WALLSTENT® Biliary Endoprosthesis is indicated for use in the treatment of biliary strictures produced by malignant neoplasms.
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use (Per 21 CFR 801.109)
OR
Over-The-Counter Use _________________________________________________________________________________________________________________________________________________________
(Optional Format 1-2-96)
David G. Severson
(Division Sign-Off) Division of Reproductive, Abdominal, ENT, and Radiological Deyi 510(k) Number